UNIGE document Scientific Article
previous document  unige:97169  next document
add to browser collection
Title

Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial

Authors
Pritchard-Jones, Kathy
Bergeron, Christophe
de Camargo, Beatriz
van den Heuvel-Eibrink, Marry M
Acha, Tomas
Godzinski, Jan
Oldenburger, Foppe
Boccon-Gibod, Liliane
show hidden authors show all authors [1 - 15]
Collaboration
Published in The Lancet. 2015, vol. 386, no. 9999, p. 1156-64
Abstract Before this study started, the standard postoperative chemotherapy regimen for stage II-III Wilms' tumour pretreated with chemotherapy was to include doxorubicin. However, avoidance of doxorubicin-related cardiotoxicity effects is important to improve long-term outcomes for childhood cancers that have excellent prognosis. We aimed to assess whether doxorubicin can be omitted safely from chemotherapy for stage II-III, histological intermediate-risk Wilms' tumour when a newly defined high-risk blastemal subtype was excluded from randomisation.
Keywords AdolescentAntineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic useChemotherapy, Adjuvant/adverse effects/methodsChildChild, PreschoolDactinomycin/administration & dosage/adverse effectsDoxorubicin/administration & dosage/adverse effectsFemaleHumansInfantKaplan-Meier EstimateKidney Neoplasms/drug therapy/pathology/surgeryMaleNeoadjuvant Therapy/adverse effects/methodsNeoplasm StagingNephrectomyTreatment OutcomeVincristine/administration & dosage/adverse effectsWilms Tumor/drug therapy/pathology/surgery
Identifiers
PMID: 26164096
Full text
Article (Published version) (353 Kb) - public document Free access
Structures
Research group Plateforme d'oncologie et d'hématologie pédiatrique (907)
Citation
(ISO format)
PRITCHARD-JONES, Kathy et al. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. In: The Lancet, 2015, vol. 386, n° 9999, p. 1156-64. https://archive-ouverte.unige.ch/unige:97169

110 hits

29 downloads

Update

Deposited on : 2017-09-29

Export document
Format :
Citation style :